Načítá se...
An update on the role of daratumumab in the treatment of multiple myeloma
Monoclonal antibodies (mAbs) have emerged as a promising new drug class for the treatment of multiple myeloma (MM). Daratumumab (DARA), a CD38 mAb, has demonstrated safety, tolerability and activity in a range of clinical trials, both as monotherapy and in combination strategies for MM. The favorabl...
Uloženo v:
| Vydáno v: | Ther Adv Hematol |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5167079/ https://ncbi.nlm.nih.gov/pubmed/28042457 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716677523 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|